Bruker (NASDAQ:BRKR) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Bruker (NASDAQ:BRKR) had its price target raised by investment analysts at JPMorgan Chase & Co. from $55.00 to $65.00 in a research note issued on Monday,Benzinga reports. The firm currently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 13.04% from the company’s current price.

A number of other analysts have also weighed in on the company. Wall Street Zen upgraded Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. TD Cowen upped their target price on Bruker from $43.00 to $45.00 and gave the stock a “hold” rating in a report on Thursday, May 7th. Barclays upped their target price on Bruker from $45.00 to $53.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. The Goldman Sachs Group reduced their price target on Bruker from $40.00 to $35.00 and set a “sell” rating on the stock in a research report on Friday, February 13th. Finally, Weiss Ratings raised Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $51.31.

Bruker Stock Up 2.0%

Bruker stock traded up $1.11 during mid-day trading on Monday, reaching $57.50. 654,246 shares of the company were exchanged, compared to its average volume of 2,446,752. The business has a fifty day moving average of $42.57 and a 200 day moving average of $43.46. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.72 and a current ratio of 1.55. The firm has a market cap of $8.75 billion, a P/E ratio of -239.19, a PEG ratio of 1.81 and a beta of 1.30. Bruker has a 12-month low of $28.53 and a 12-month high of $64.54.

Bruker (NASDAQ:BRKR) last posted its earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. The company had revenue of $823.40 million during the quarter, compared to analyst estimates of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.Bruker’s revenue was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Research analysts anticipate that Bruker will post 2.12 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total value of $79,800.00. Following the transaction, the vice president directly owned 128,443 shares of the company’s stock, valued at $5,124,875.70. This represents a 1.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 27.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Bruker

Several hedge funds have recently made changes to their positions in BRKR. Los Angeles Capital Management LLC acquired a new position in shares of Bruker in the 4th quarter valued at $26,000. Allworth Financial LP increased its position in shares of Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 257 shares during the period. Essential Partners LLC acquired a new position in shares of Bruker in the 1st quarter valued at $36,000. Parallel Advisors LLC increased its position in shares of Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 479 shares during the period. Finally, Summit Securities Group LLC acquired a new position in shares of Bruker in the 4th quarter valued at $50,000. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.